CagriSema

CagriSema combines cagrilintide with semaglutide in a fixed-dose investigational preparation. Phase 3 research examines this combination for metabolic disease and weight management. It has no FDA approval.

• Weight Loss

  Most effective

  Weight-management research examines substantial, sustained reductions in body weight.

  Human, randomised · 1 reference

• Blood Sugar Control

  Most effective

  Potential metabolic benefits include improved glucose regulation and lower A1C in type 2 diabetes.

• Cardiovascular Health

  Effective

  Cardiovascular research examines fewer adverse cardiovascular events among people at high risk.

• Metabolic Syndrome

  Effective

  Metabolic-syndrome research considers simultaneous improvements across several components of the condition.

• Other GLP-1 Agonists (e.g. Semaglutide + Tirzepatide)

  Avoid

• Insulin

  Monitor

• Sulfonylureas

  Monitor

• Metformin

  Compatible

• SGLT2 Inhibitors

  Compatible

• Oral Contraceptives

  Caution

• Warfarin / Blood Thinners

  Monitor

• NAD+

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

1. Take the CagriSema vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

Week 1–2

Appetite may begin to decline, while nausea or a sense of fullness can occur during early adjustment.

Week 2–4

Cravings and portion sizes may decrease noticeably, with the first changes in body weight.

Week 4–8

Appetite control may strengthen and weight may fall steadily; blood sugar may also improve when relevant.

Week 8–16

Larger weight changes, better energy and early improvements in metabolic markers may emerge.

Week 16–24

Further weight-loss milestones may coincide with cardiovascular benefits and a more favorable lipid profile.

Week 24+

The anticipated later phase includes the greatest effect, broader metabolic improvements and continuing benefit. These intervals are research expectations, not established individual outcomes.

• Nausea that is usually temporary and varies with dose · Most common
• Diarrhea or constipation while increasing the dose
• Vomiting, particularly after initiation or dose increases
• Lower appetite and feeling full sooner
• Redness or bruising around the injection site
• Tiredness, especially during the first weeks
• Pancreatitis; stop use immediately if severe abdominal pain develops · Rare
• Effects on thyroid C cells · Rare

Contraindications

• Avoid use if you have MEN2 or a history of thyroid cancer.

CagriSema: investigational in the US.

• US

  Investigational

  FDA — no approval; the fixed-dose combination remains in Phase 3 development.

  Rx required

  No

  503A

  Allowed

  Telehealth

  N/A

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. (2021)

   PMID 33894838DOI 10.1016/S0140-6736(21)00845-X

2. Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial (2023)